Background: Being in a period with extensive brain maturation, adolescents with early-onset schizophreniaspectrum disorders (EOS) provide unique neurodevelopmental data that may contribute to a better understanding of schizophrenia at all ages. Cognitive dysfunction is a central feature of schizophrenia and is more pronounced in EOS than in later onset illness. However, there is limited research on both the long-term course of global cognition in EOS, and how cognition over time is influenced by clinical characteristics during the early illness period. Methods: Thirtyone EOS patients and 73 controls (age 12-18) were assessed on clinical variables at baseline (PANSS, duration of untreated psychosis [DUP], hospitalizations, suicide attempts, and remission). Neuropsychological assessments with the MATRICS Consensus Cognitive Battery (MCCB) were conducted at baseline and after both 1 and 2 years, and composite scores of total performances were calculated. The analyses were performed with a linear mixed model. Results: The present study found that global cognition followed a stable course over the first years of the disease in EOS, though at a significantly lower level in EOS compared with the controls. We did not detect a relationship between DUP, remission, positive/negative symptoms, and hospitalizations on one hand, and long-term cognition on the other hand, but PANSS-general and suicide attempt history at baseline were identified as risk factors of longitudinal cognitive function. Conclusions: Though at different levels, the EOS group and the controls had a similar cognitive course over 2 years. Some baseline characteristics (psychotic symptoms, DUP, remission, and hospitalization) had no influence on cognition within the first 2 years of illness. In contrast, general symptoms and a history of suicide attempts at baseline were more potent risk factors of the cognitive course than the psychoticspecific symptoms, and should, therefore, be subject to specific attention in the evaluation and treatment of patients with early-onset psychosis.
Introduction
A major objective in schizophrenia research is to find reliable prognostic factors that may help identify therapeutic targets and allocate resources to those with the greatest needs. Approximately 5% of the schizophrenia population has an illness onset before 18 years of age, which is often referred to as earlyonset schizophrenia-spectrum disorders (EOS; Cannon et al., 1999) . Research suggests that EOS reflects increased disease severity, with a worse clinical course and outcome (Remschmidt et al., 2007; Schimmelmann, Conus, Cotton, McGorry, & Lambert, 2007) . The cognitive profile in EOS seems to be similar to adult-onset schizophrenia (AOS; Holmen, Juuhl-Langseth, Thormodsen, Melle, & Rund, 2010; Kravariti, Morris, Rabe-Hesketh, Murray, & Frangou, 2007; Oie, Sundet, & Ueland, 2011) , but more impaired (Jepsen et al., 2013; Nieto & Castellanos, 2011; Rajji, Ismail, & Mulsant, 2009) , and with a more pronounced developmental and premorbid anomaly (Frangou, 2013; Kumra & Charles Schulz, 2008; Teigset, Mohn, & Rund, 2016) . EOS patients develop symptoms in a period with extensive brain maturation and alterations in cognitive structures and functions (Juuhl-Langseth, Holmen, Thormodsen, Oie, & Rund, 2014) ; thus, they provide unique neurodevelopmental data that may contribute to a better understanding of schizophrenia at all ages (Bombin et al., 2013; Rapoport, Giedd, & Gogtay, 2012; Remschmidt, 2002) .
Although cognitive deficits do not appear in all cases (Rund, Zeiner, Sundet, Oie, & Bryhn, 1998) , they are considered to be a core feature of schizophrenia (Palmer, Dawes, & Heaton, 2009; Rund et al., 2006; Torgalsboen, Mohn, & Rishovd Rund, 2014; Townsend & Norman, 2004) , and they are more pronounced in schizophrenia than in bipolar disorders (Landro, Orbeck, & Rund, 1993; Seidman et al., 2013) . While some studies argue for specific deficits, others suggest deficiencies across Weinberger, & Dickinson, 2013) . A natural consequence of this has been a more frequent use of composite scores in cognitive studies of schizophrenia (Meyer et al., 2014; Rund et al., 2015) .
The trajectories of cognitive deficits over the course of the disease are being debated, and one question has been whether schizophrenia involves neurodegeneration (Rund, 2009 ). To date, most longitudinal studies indicate a stable cognitive course in AOS (Bora, 2015; Rund et al., 2015) , with a growing body of research suggesting a similar stability in EOS (Bombin et al., 2013; Frangou, Hadjulis, & Vourdas, 2008; Juuhl-Langseth, Holmen, Thormodsen, Oie, & Rund, 2014; Mayoral et al., 2008; Oie, Sundet, & Rund, 2010) . However, the course of global cognition over the first years, as measured in composite scores, has yet to be reported in EOS. A further objective is to identify factors affecting the cognitive course. While both cognition and clinical variables have been subject to comprehensive research in schizophrenia, the interaction between the two has gained less attention, especially in EOS. An essential question is to what extent the longitudinal course of cognition is influenced by clinical characteristics in the early illness period.
Previous research from AOS diverges on the association between psychotic symptoms and cognition, both at baseline (Harvey, Green, Bowie, & Loebel, 2006; Rund et al., 2004; Ventura, Thames, Wood, Guzik, & Hellemann, 2010) and longitudinally (Bagney et al., 2015; Barder et al., 2013; Fervaha, Foussias, Agid, & Remington, 2014; Hoff et al., 1999; Mayer, Salovey, & Caruso, 2002; Meier et al., 2014; Rund et al., 2015) . Research that examines baseline correlations suggests that negative symptoms interact with cognition to a greater extent than positive symptoms (Bora, Yucel, & Pantelis, 2009; Kravariti et al., 2012; O'Connor et al., 2013) , with one long-term study reporting that negative symptoms may help mediate the relationship between cognition and functioning (Meyer et al., 2014) . Other longitudinal findings report associations between a reduction in positive symptoms and cognitive improvement (Hoff et al., 1999) , or a small to no relationship between positive/negative symptoms and cognition (Rund et al., 2004) .
Research on youths with bipolar disorder indicates increased cognitive deficits due to symptom severity and psychotic features (Arango, Fraguas, & Parellada, 2014; Fitzgerald et al., 2004; McCarthy, Weiss, Segovich, & Barbot, 2016; Udal et al., 2013) . In youths with schizophrenia-spectrum disorders, we find only one study that has investigated the longterm interaction between psychotic symptoms and cognition (Wozniak, Block, White, Jensen, & Schulz, 2008) . They revealed no association between cognition and psychotic symptoms, with the exception of a lower IQ predicting more negative symptoms after 1 year. However, their study had a short follow-up period and other clinical characteristics were not examined, thereby raising questions about the relationship between a wider range of symptoms and cognition, in addition to whether the deterioration endures over time. Furthermore, the disappearance of psychotic symptoms may also affect long-term cognition, although the relationship between remission and cognition has yet to be investigated in EOS. Nevertheless, in an adult sample, Rund et al. (2015) found that a stable remission without relapse in the first year seemed to predict a better cognitive course.
Another relevant clinical variable is illness duration. The 'neurotoxicity hypothesis' suggests that a longer duration of untreated psychosis (DUP) accelerates cognitive deterioration (Wyatt, 1991) . In adult samples, some longitudinal studies report that a shorter DUP leads to a better overall cognitive functioning (Cuesta et al., 2012; Dominguez et al., 2013; Yamazawa et al., 2008) , but the majority of studies report no such association (Goldberg et al., 2009; Melle et al., 2008; Rund, 2014; Rund et al., 2007 Rund et al., , 2015 . Research on the interaction between DUP and cognition in EOS is rare. One baseline study found no immediate effect of illness duration on cognitive performance in EOS (Kravariti, Morris, Rabe-Hesketh, Murray, & Frangou, 2003a) , while another longitudinal study found that a shorter illness duration was associated with a greater improvement in executive functions after 2 years . Whereas the majority of AOS studies reported no association between DUP and cognitive course (Goldberg et al., 2009; Melle et al., 2008; Rund et al., 2007 Rund et al., , 2015 , the findings of Fraguas et al. (2014) suggest a possibly worse impact of DUP on cognition in EOS compared with AOS.
A final research question concerns the relationship between nonpsychotic symptoms and cognition. About half of all schizophrenia patients attempt suicide, and 9%-13% ultimately do commit suicide (Potkin, Anand, Alphs, & Fleming, 2003) , as depression and insight seem to be important predictors (Hor & Taylor, 2010) . Even so, little is known about the relationship between suicidality and cognition in EOS, and results are inconsistent in AOS; some indicate an association between a higher cognitive function and a history of suicide attempts, while others find no such association (Delaney et al., 2012; Kim, Jayathilake, & Meltzer, 2003; Potkin et al., 2003; Zoghbi et al., 2014) .
If clinical characteristics at baseline can predict the cognitive course in EOS, this is essential for prognosis and therapy. In the present study, we first report how the cognitive composite score develops over time in EOS, compared with healthy controls. However, the primary aim of this paper is to investigate to what extent the cognitive course in EOS is influenced by clinical characteristics during the early illness period, such as symptoms of schizophrenia, DUP, remission, suicide attempts, and number and duration of hospitalizations caused by psychosis.
Method
Some assessments of the longitudinal trajectory in the current EOS group have already been reported (Juuhl-Langseth et al., 2014) and revealed stable deficits in all cognitive domains, with the exception of working memory and processing speed. Because of drop-outs, only 65% of the patients were included in the analyses at the last time point. In the present study, we analyzed cognitive composite scores and used statistical analyses (linear mixed model) that allow the inclusion of all participants with at least one neurocognitive evaluation.
Subjects
The present paper is part of the Early-onset Study, a longitudinal study carried out at the University of Oslo. Patients were consecutively recruited between 2005 and 2009 and were tested three times: at baseline, after 1 year, and after 2 years (Holmen et al., 2010; Juuhl-Langseth et al., 2014; Thormodsen, Juuhl-Langseth, Holmen, & Rishovd Rund, 2012) . The patients were recruited from various inpatient and outpatient units in Eastern Norway, and inclusion criteria were age (12-18 years) and the diagnosis of schizophrenia-spectrum disorder according to DSM-IV. Exclusion criteria were central nervous system pathology, head injury (loss of consciousness for more than 30 min and/or any neurological sequelae), or an estimated IQ of less than 70.
A total of 31 patients were included at baseline (T1), and schizophrenia-spectrum disorders describe the whole sample, with a diagnosis of schizophrenia: n = 17 (54.9%; including paranoid schizophrenia, catatonic schizophrenia, schizophrenia undifferentiated, and residual schizophrenia), schizophreniform psychosis: n = 1 (3.2%), schizoaffective disorders: n = 3 (9.7%), and psychosis not otherwise specified (NOS): n = 10 (32.3%). The percentage distribution of diagnoses stayed relatively stable; after 1 year (T2), 55% (n = 12) were diagnosed with schizophrenia, 14% (n = 3) with schizoaffective disorders, and 18% (n = 4) with psychosis NOS. After 2 years (T3), 55% (n = 11) of the EOS patients were diagnosed with schizophrenia, 20% (n = 4) with schizoaffective disorders, and 10% (n = 2) with psychosis NOS. Three patients had no diagnoses at T3, two of whom had psychosis NOS, and one residual schizophrenia at baseline. At T1, 74% of the patients received antipsychotic medication, 41% of them were medicated at T2, and 50% at T3. At T1, all received secondgeneration antipsychotic medication [Quetiapine (n = 5), Risperidone (n = 3), Ziprasidone (n = 3), Aripiprazole (n = 4), Olanzapine (n = 7), and Clozapine (n = 1)], three in combination with first-generation anti-psychotics, four in combination with anti-depressants, two in combination with benzodiazepines, and one in combination with mood stabilizers. Calculated daily doses (CDDs; WHO, 2010) in mean at T1 was 1.2, at T2 1.5, and at T3 1.4 for antipsychotic medication. CDDs of medication were based on the international daily dose of medication technical measurement system (WHO, 2010) , where the CDD is the outcome of the prescribed daily dose divided by the average recommended daily dose of medication. The results were previously reported by Juuhl-Langseth et al. (2014) , who found no significant change in CDD over time and no relationship between medication and cognitive performance. The mean age of the EOS group was 15.6 years at baseline. No deaths occurred in our sample in the timeframe measured.
The healthy controls (HCs) were randomly selected from the Norwegian population register and contacted by letter, or they were contacted through advertisements at four schools in Eastern Norway. The invited participants came from the same age group as the patients (12-18 years), and an equal amount of boys and girls were invited. All patients and HC attended regular school classes at normal grade levels. The HCs were screened for mental problems using the Mini-International Neuropsychiatric Interview (M.I.N.I.) screening module (Sheehan et al., 1998) and were excluded from the study when disqualified by the screening criteria.
A total of 31 patients and 73 healthy controls were included at baseline and were followed longitudinally. The number of participants who attended the study at T2/T3 was EOS 22/20 and controls 41/40; and the participants who completed all the tests included in the composite score were 29 patients at T1, 18 at T2, and 18 at T3 in the EOS group; in the control group, there were 67 participants at T1, 39 at T2, and 40 at T3 (Table 1 ).
All participants were given a complete description of the study, and written informed consent was obtained from both the patients and their parents, if the participant was younger than 16. The study was approved by the Regional Committee for Medical Research Ethics (REK Sør-Øst) and the Norwegian Data Inspectorate.
Clinical assessments
The clinical and cognitive assessments were carried out by trained clinical psychologists. All baseline tests were performed within 8 weeks after inclusion in the study. Diagnostic evaluations were based on the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), modules A-D. The interviewers participated in regular diagnostic consensus meetings led by well-experienced clinical researchers and completed the training course in SCID assessment arranged by the University of California, Los Angeles (UCLA). The mean overall kappa as assessed in the UCLA training course was .77 (Holmen et al., 2010) .
For the assessment of psychotic symptoms and functioning, the Positive and Negative Syndrome Scale (PANSS; Kay, Fiszbein, & Opler, 1987) was used, and we calculated the PANSS baseline scores for the positive, negative, and general component. The age of onset was defined by a PANSS score of 4 or more on the Positive or General Scale (see DUP), and the mean age of onset in the group was 14 years (range 10-17). Moreover, only baseline scores were used in the analyses. However, Juuhl-Langseth et al. (2014) previously reported stability in symptom levels over the three time points and found no significant changes over time in positive, negative, or general symptoms, thereby securing that the baseline group did not differ significantly from those who participated at T2 and T3. Global functioning was measured at baseline with the Global Assessment of Functioning-Split version (Split-GAF; Pedersen, Hagtvet, & Karterud, 2007) . As in the symptom scales, there were no significant changes in split-GAF (symptoms or function) from T1 to T3 (mean at T1/T2/T3; symptoms 47.5/54.3/58.4, function 47.8/58.1/58.2). DUP was measured by the time interval from the first onset of psychotic symptoms; defined as the first week with a PANSS score of 4 or more on one of the Positive Scale items 1 (delusions), 3 (hallucinatory behavior), 5 (grandiosity), 6 (suspiciousness/persecution), or General Scale item 9 (unusual thought content) to the start of the first adequate treatment of psychosis (defined as the start of adequate antipsychotic medication or admission to the hospital for treatment).
Suicide attempts were assessed in the clinical interviews by asking the youths if they had ever attempted to kill themselves, and if yes, how many times. As reported by the patients, the total number of suicide attempts before baseline was recorded. In the group of 31 patients, 6.7% reported one suicide attempt, 10% had two attempts, 3.3% had three attempts, and 3.3% had five attempts.
Hospitalization was measured by the number of times a patient was admitted to psychiatric inpatient treatment due to psychotic symptoms before baseline assessment. The total length of inpatient treatment was measured in weeks, while the mean length of hospitalization in the group was 28.7 weeks (range 0-138).
Remission was defined by the disappearance of psychotic symptoms for at least 7 days before baseline, as defined by the same PANSS symptoms as defined in DUP (see above). Of those in remission, 20% were in remission for 7 days, 10% for 14 days, whereas 70% were in remission for 8-17 weeks.
Neuropsychological assessments Nuechterlein et al., 2008) has been widely used in AOS samples and is found to have good test-retest reliability and a limited practice effect (Keefe et al., 2011; Rajji et al., 2013) .
The MCCB covers the following seven domains (Nuechterlein & Green, 2006) (Mayer et al., 2002) ]. In addition, a composite sum score was calculated using the arithmetic average of the first six domains (the average T-score across domains). At the time of neurocognitive assessments of patients in this study (2005) (2006) (2007) (2008) , the psychometric properties for the MSCEIT for this age group were unknown, and this test was not used.
Because there are no norms for the MCCB scores of tests respondents below the age of 20, we calculated our own Tscores with a mean of 50 and an SD of 10. General intellectual function (IQ) was assessed according to norms using the four subtests of the Wechsler Abbreviated Scale of Intelligence (WASI; Vocabulary, Similarities, Block Design and Matrix Reasoning; Wechsler, 2007) .
Missing data
Investigations of missing data in the variables were performed. For technical reasons, a few participants (two patients at T1; four at T2 and two at T3; and six healthy controls at T1, two at T2, and none at T3) were unable to complete every test of the battery included in the composite score. For the composite score, the proportion of incomplete or missing values did not differ significantly between the groups, genders, and quartiles of age at each time point. Missing data on outcomes were, therefore, assumed to be at random. Linear mixed models analysis gives unbiased results provided that the data are not predicted by the baseline covariates.
All the potential risk factors were measured only at T1. Among potential risk factors (PANSS, DUP, number of times on hospital, remission, and suicidality), PANSS has three missing values, suicidality has one missing value, and remission has two missing values.
Statistical analyses
All analyses were performed using SPSS Statistics (version 20, IBM Corp, Armonk, NY) or STATA 14.0 software (StataCorp, 2015) . To account for missing data and confounding variables, all analyses were performed with a linear mixed model that has been recommended for repeated measures (Gueorguieva & Krystal, 2004) . The method has been found to preserve sample size in small longitudinal psychological studies despite missing data, an advantage over repeated-measures ANOVA, and provide similar measures of significance (Muth et al., 2016) .
To estimate differences between the groups over the entire follow-up period (i.e. baseline, T2, and T3) for cognitive composite scores as outcome and control for repeated measurements, we used linear mixed models. Time (measured in years after inclusion), group, and time-by-group interaction were fixed effects in all models. All models included random intercept. Based on the linear mixed model, we estimated mean values with 95% confidence intervals (CI) for the three time points (baseline, T2, and T3) for each group. We also estimated the mean group changes from baseline to 2 years (Table 2) .
To identify risk factors of the longitudinal cognitive composite scores in the patient group, linear mixed models analyses were performed. All models included fixed effects for time as a continuous variable. The following clinical variables at baseline were considered for inclusion: in DUP, in the PANSS (positive, negative, and general) baseline scores, in suicide attempts, in Split-GAF (symptoms and function), in remission, and in hospitalizations (number of times and total weeks). Any variable with a p < .15 from the univariable analysis were included as fixed factors in the multivariable model. A manual backward stepwise elimination procedure using a multivariable regression model was performed to identify independent risk factors. In all models, a random intercept was included.
Interaction effects between time and the fixed factors were checked by including product terms, one at a time, into the models. The interaction term describes whether the composite score changes differently over time at different levels of the risk factor. Multivariate analyses were preceded by estimation of correlation between risk factors.
Results
Our findings for the cognitive composite score in the EOS group and the HC group over the three assessments, from baseline to the 2-year follow-up, are illustrated in Figure 1 and compared to patients. The difference was still not statistically significant. To identify possible risk factors of the longitudinal composite score, linear mixed model analyses were performed. The univariable analyses did not detect a relationship between Split-GAF, remission or hospitalizations (times or length), and the composite score, and were, thus, not included in the multiple regression analysis.
From the univariable analysis DUP, all the PANSS variables (positive, negative, and general) and the number of suicide attempts were identified as possible risk factors of the longitudinal composite score (p < .15). However, since the PANSS (positive, negative, and general) baseline scores were strongly correlated, only PANSS general baseline score was included in multivariable analysis, as it was identified as the strongest risk factor. Multiple regression analysis showed that PANSS general and suicide attempt history at baseline were the only risk factors that were associated with the longitudinal cognitive course. We found no significant interactions between time and the risk factors. The results are shown in Table 3 .
When comparing the dropouts (attended solely at T1) with the ones who continued to T2 and/or T3, the EOS dropouts were more compromised with regard to baseline cognitive functioning (composite scores) than the patients who remained in the study (t(27) = 3.3, p < .01). These differences did not appear in the control group.
Discussion
The mixed model supported what is previously reported in the Early-onset Study (Juuhl-Langseth et al., 2014) , as well as other longitudinal studies (Frangou et al., 2008; Jepsen, Fagerlund, Pagsberg, Christensen, Hilker, et al., 2010) , namely that there seems to be a deficit in the cognitive function in EOS compared with controls, and that the course is relatively stable over a period of 2 years. Since the control group functioned above average in IQ, this might have affected the results. When adjusting for IQ in the analyses, the controls did experience a larger cognitive change compared with patients. However, the difference was not significant. Furthermore, the EOS dropouts had larger cognitive deficits at baseline than the ones that stayed in the study, which could imply a different cognitive course for these patients. Nevertheless, a stable global cognitive course indicates that degeneration, defined as a progressive neurodegenerative process after illness onset, does not occur in EOS within the few first years of diagnosis, a finding which is consistent with most previous studies (Frangou et al., 2008; Jepsen, Fagerlund, Pagsberg, Christensen, Hilker, et al., 2010) , but not all (Oie et al., 2010) .
We found that a higher amount of general symptoms (PANSS) at baseline significantly predicted a deteriorated longitudinal composite score in EOS. In the separate univariate analyses, both positive symptoms (PANSS) and negative symptoms (PANSS) predicted the cognitive course. However, they both lost their predictive value in the multiple regression analyses. Our findings are in line with previous research from AOS that detects no significant longterm relationship between positive/negative symptoms and cognition (Harvey et al., 2006; Rund et al., 2004 Rund et al., , 2015 , thus indicating a continuity between EOS and schizophrenia with later onset. Like us, Wozniak et al. (2008) found no significant relationship between psychotic symptoms and cognition in adolescent schizophrenia. Yet, their study did not report an evaluation of general symptoms (Wozniak et al., 2008) . The general psychopathology scale of the PANSS measures the severity of the schizophrenic illness (Kay et al., 1987) . While the positive and negative scales measure the amount of typical psychotic symptoms, the general scale includes 16 nonspecific psychiatric symptoms, such as depression, anxiety, guilt feeling, and social avoidance. In our study, we examined the total score and not the symptoms separately. Our study, therefore, gives no indication of the relative effect of specific symptoms included in the scale. However, our findings suggest that general symptoms are a more potent predictor of the neurocognitive course in EOS than the psychotic symptoms. This may imply that cognitive deterioration is influenced by a strong affective response to the illness, rather than a result of irrational or psychotic symptoms in and of themselves.
As with later onset schizophrenia, the youths with schizophrenia-spectrum disorders have an increased risk of suicide within a year after the onset of psychosis (Sanchez-Gistau et al., 2013) , particularly if they have a history of depression and previous suicide attempts (Melle, 2013) . Our results indicated that a history of suicide attempts was related to cognitive deterioration. An association between suicidality and neurocognitive functioning in AOS has also been reported in some studies, suggesting a relationship between hopelessness, a greater insight into one's own illness, and a higher cognitive functioning on the one side, and a higher risk of (Delaney et al., 2012; Kim et al., 2003) , while other studies report no such associations (Potkin et al., 2003; Zoghbi et al., 2014) . To the best of our knowledge, no previous research has investigated the relationship between suicide attempts and long-term cognition in EOS. Hence, our study is the first to demonstrate that a history of suicide attempts at baseline predict a worsened neurocognitive course in EOS. This relationship should be understood in the context of general symptoms, because both suicidal ideation and suicide attempts most likely interact with several symptoms on the general scale, that is, depression and social avoidance. As suggested by Fialko et al. (2006) , suicide attempts in psychosis appear to be caused by an entire range of general symptoms, rather than by the psychotic symptoms alone. Those who suffer from psychosis are often met with stigma, pessimism, and exclusion in society (van Os & Kapur, 2009) , consequently adding an extra burden to the illness that may affect both general symptoms and suicidality. Furthermore, suicide attempts have been associated with impulsivity as measured by neurocognitive tests (Wang et al., 2014; Wu et al., 2009) . Impulsivity is often also connected to cognitive deterioration (Arce & Santisteban, 2006) , and both suicide attempts and impulsivity may indicate a higher level of general symptoms. Our findings of a relationship between a history of suicide attempts at baseline and a deteriorated global cognition in EOS after 2 years should be replicated in studies with longer follow-up periods, to examine whether the cognitive worsening endures. Still, the high rate of suicidality in schizophrenia strongly suggests that suicidal ideation and history need to be determined, and protective measures have to be taken while planning the inpatient and outpatient treatment of these patients. Our study indicated a stable longitudinal cognitive course in EOS, but also that high PANNS general symptoms and number of suicide attempts at baseline predicted cognitive deterioration, which may indicate heterogeneity within the EOS group. Thus, there may be a subgroup of patients who deteriorates over time due to higher levels of general symptoms and suicidality. However, our sample size is too small to isolate such a subgroup, but the hypothesis should be subject to investigation in future research with larger sample sizes.
Like a majority of studies from AOS (Rapp et al., 2013; Rund, 2014; Rund et al., 2015) , we found no significant influence of DUP on long-term cognition in EOS; thus, there were no signs of neurotoxicity at least in the timeframe measured. In adolescence, the brain matures extensively, and one could assume that a longer DUP would have a more severe impact on cognition in this time period. Nonetheless, we detected no indication of DUP being more critical in adolescent psychosis than in adult psychosis. In line with our findings, Kravariti et al. (2003a) found no significant effect of illness duration on baseline cognitive performance in EOS. Nevertheless, the results of Fraguas et al. (2014) indicated that DUP predicts reduced long-term executive functioning in EOS. A possibility is that DUP affects executive functions more severely than other cognitive domains, and by evaluating composite scores in our study, the impact was diffused.
Furthermore, our study did not reveal a significant relationship between Split-GAF and cognition or between remission before baseline and the longitudinal composite score. In an adult sample, Rund et al. (2015) found that stable remission without relapse in the first year predicted a better cognitive course, implying that patients with a stable remission respond better to treatment and have good prognosis and cognitive trajectories. A possible cause for the divergent results is that remission in a younger population is more unstable and, therefore, not a good predictor of cognitive development in EOS. In our study, we defined remission by the disappearance of psychotic symptoms for at least 7 days, which is short. It has previously been suggested that 6 months is an indication of clinical remission via the PANSS (Andreasen et al., 2005; Opler, Yang, Caleo, & Alberti, 2007) . Even though 70% of the patients in our EOS group were in remission over a period of 8-17 weeks, none of the patients were symptom free for more than 5 months before baseline. As a result, remission in our group seemed quite unstable and would have been nonexistent with a stricter definition of remission (6 months).
The present study found no significant relationship among the number of hospitalizations, length of stay in institutions, and longitudinal cognition. Even though long-term institutional stays have decreased markedly, hospitalizations occur, often caused by severe psychosis. A recent review concludes that there are minimal indications of cognitive changes due to institutionalizations, whether long or short (Harvey, Loewenstein, & Czaja, 2013) , which is supported by our findings.
A limitation of our study is the modest sample size, hence opening for the possibility that a larger sample might reveal more significant associations between clinical variables and long-term cognition. The incidence of EOS is very low, and we included all potential participants in Norway over a period of 4 years and arrived at a group size that complies with other EOS studies (Frangou et al., 2008; Jepsen, Fagerlund, Pagsberg, Christensen, Hilker, et al., 2010; Oie & Rund, 1999) , with a similar attrition rate Kravariti et al., 2003a,b; Wozniak et al., 2008) . Also, the sample size matches comparable EOS and first episode schizophrenia studies using the same neuropsychological test battery (Fu, Czajkowski, Rund, & Torgalsboen, 2017; Holmen et al., 2010) . Furthermore, the drop-out of patients and missing data represent a limitation. In longitudinal studies, the ideal is to have a complete set of data and no drop-outs, but this has been difficult to achieve. The mixed model has been recommended over repeated-measures ANOVA in longitudinal psychological studies with small sample sizes, because of its ability to accommodate missing data points (Krueger & Tian, 2004; Muth et al., 2016) . Still, results based on missing data should always be interpreted with caution. As already mentioned, the dropouts in the EOS group had more profound cognitive deficits than the ones who continued, which raises questions about the generalizability of the results. However, in relation to the risk factors measured at T1, the EOS patients at baseline were clinically very similar to those who participated at T2 and T3, both in diagnoses, symptoms, and global functioning. Moreover, only one of the patients who had attempted to commit suicide before baseline left the study, thereby indicating that our findings were minimally influenced by drop-outs.
A further limitation concerns medication effects. Approximately 70% of the patients received secondgeneration anti-psychotics, and we had limited control over medication effects in relation to cognitive achievements. In one study, longer exposure to medication has been reported to predict a lower level of performance in aspects of attention, psychomotor processing speed, and spatial working memory (Kravariti et al., 2003a) . However, previous analyses of the current material did not detect a relationship between medication and cognitive performance (Juuhl-Langseth et al., 2014) .
A final limitation concerns the measurement of clinical variables, especially the unreliable assessment of suicide attempts that was solely based on the patients' self-reports. It is difficult to obtain reliable measures concerning suicide attempts. However, the clinical psychologists involved in the assessments attended regular diagnostic consensus meetings led by well-experienced clinical researchers throughout the entire assessment process, to help ensure inter-rater reliability.
The strengths of the present study are the use of a standardized comprehensive neurocognitive test battery, the MCCB, which facilitate comparisons in future research. Because of the low frequency of EOS, the patient group provides valuable information about baseline cognitive functioning, in combination with a minimized effect of confounding variables associated with chronicity. Furthermore, the longitudinal follow-up studies are of great importance in detecting neurocognitive trajectories in schizophrenia (Bora, Yucel, & Pantelis, 2010; Gur et al., 2014; Rund, 1998) .
Conclusions
The EOS patients followed much the same stable cognitive course as found in schizophrenia patients with a later onset, thus confirming continuity between early-onset and AOS. Despite the small sample size, clinical characteristics in the early illness period, such as DUP, remission, and hospitalization, did not seem to influence the neurocognitive course. Our findings indicate that higher scores of general symptoms, as well as suicide attempt history, predict a deteriorated cognitive course, and should be subject to specific attention in the evaluation and treatment of patients with early-onset psychosis.
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symptoms alone, and should be subject to specific attention in the evaluation and treatment of patients with early-onset psychosis.
• Schizophrenia patients have a high rate of both suicide and suicide attempts. The present study found that a former history of suicide attempts predicted a deteriorated cognitive course in EOS. Other clinical variables like psychotic symptoms, DUP, remission, and hospitalization did not affect the long-term cognitive course in EOS.
